Publications by authors named "A Soumana"
Drug-resistant tuberculosis (DR-TB) poses a significant public health challenge, particularly in resource-limited settings. The prevalence and management of DR-TB in African countries require comprehensive strategies to improve patient outcomes and control the spread of the disease. Aggregated routine data (from 2018 to 2022) on multidrug-resistant TB (MDR-TB) were collected from the National TB Programs (NTPs) from all six countries.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluates how text mining (TM) influences the effectiveness of screening methods for systematic reviews, focusing on both sensitivity and specificity.
- Five screening approaches were compared, including traditional double screening and various TM-assisted methods, using a standardized reference from a published systematic review.
- Results indicated that TM methods provided similar sensitivity to the conventional approach but modestly improved specificity, leading to significant time savings in the screening process.
Objectives: High-dose rifampicin (R) and isoniazid (H) are known to be safe but were not yet combined in a single regimen. The primary objective of the TRIple-DOse RE-treatment (TRIDORE) study is to determine whether a 6-month firstline regimen with triple dose of both R and H (intervention arm; 6RHZE) is non-inferior in terms of safety compared to a normal-dose regimen (6RHZE) in previously treated patients with R-susceptible (Rs) recurrent tuberculosis (TB).
Design/methods: TRIDORE is an ongoing pragmatic open-label multi-stage randomized clinical trial.
Article Synopsis
- The project aimed to implement contact investigation (CI) methods in national tuberculosis programs across eight countries, focusing on children under 5 years and people living with HIV (PLHIV).
- Over 9,000 home and clinic visits were conducted, revealing that 2.6% of children and 10.1% of PLHIV screened were diagnosed with active TB, with a high treatment uptake for both groups.
- The initiative showed that CI can be effectively scaled up within existing TB programs in several African countries, leading to a successful implementation in six out of the eight participating nations by the end of 2021.